| GSK & QB3@953 help launch Telo Therapeutics|
Telo Therapeutics, is a start-up biotechnology company co-founded by Joe Costello, PhD, UCSF Professor of Neurological Surgery, and Robert Bell, PhD, a former post doc in Dr. Costello's lab. GSK's Discovery Partnerships with Academia (DPAc) group recently extended its 2015 collaboration agreement with QB3@953, and has now formed a collaboration with Telo Therapeutics to develop a novel precision medicine with the aim to reverse cancer cell immortality. Press release here
GraphWear is replacing blood and urine diagnostic tests with a non-invasive sweat test. Sweat is diluted and ultra-filtered blood and has the same bio molecular information as blood, only in minuscule concentrations. GraphWear has developed a non-invasive flexible sensor that can tap into this information for real-time healthcare monitoring, using nanotechnology.
Sepsis (a complication of some infections) is associated with half of all in-hospital deaths, and is the single most expensive diagnosis nationally ($24 billion). There is no rapid gold standard diagnostic, so physicians largely guess at presence and severity of infection. Blood cultures, which may take 24-48 hours to return, only turn positive in ~30% of all patients with infections, and so are not effective for ruling out infections. Inflammatix (pronounced in-flah-MATT-iks) has a breakthrough solution: we 'read' the immune system to determine the presence, type (bacterial/viral) and severity of infection. The technique works by measuring the expression levels of several host immune genes, and then applying proprietary Inflammatix algorithms to produce clinically actionable results. The Inflammatix gene sets have been extensively validated (24 validation cohorts, >1000 patients) and published in top-tier medical journals.
Please join us as we toast the growth and success of Miroculus and wish them well as they move to SOMA in San Francisco. Celebrations will be on Thursday, March 30, 2017 at 3:30 PM.
| Amgen Seminar and Office Hours: March 17, 2017, 12:30 PM - 4:00 PM|
12:30 PM Networking and Lunch
1:00 PM "From bench to bedside - and you thought molecule identification was difficult!" Sean Lybrand, Director of Value, Access and Policy, Amgen Australia
2:00 - 4:00 Amgen Office Hours
Janis Naeve, Managing Director of Amgen Ventures and Samantha Palmer, Senior Licensing Manger, Amgen
To apply for Office Hours with Amgen, please contact Linda Eng.
Janis Naeve PhD joined Amgen in 2005 and is the Managing Director of Amgen Ventures, guiding the fund's investment in biotechnology companies focused on discovering and developing human therapeutics. From 2002 to 2005, Dr. Naeve was director of Corporate Development at X-Ceptor Therapeutics, acquired by Exelixis.
Samantha Palmer PhD joined Amgen in 2015 and is the Senior Licensing Manager for Inflammation. She has an extensive background in immunology and microbiology and leads the Inflammation product search and evaluation efforts for Amgen business development covering Rheumatology, Dermatology, Respiratory and Specialty Gastro-Intestinal diseases.